The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2019

Filed:

May. 13, 2016
Applicant:

Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;

Inventors:

Sei-Ryang Oh, Daejeon, KR;

Kyung Seop Ahn, Daejeon, KR;

Su Ui Lee, Daejeon, KR;

Hyung Won Ryu, Daejeon, KR;

Doo-Young Kim, Daejeon, KR;

Hyeong Kyu Lee, Daejeon, KR;

Ok-Kyoung Kwon, Daejeon, KR;

Jung Hee Kim, Daejeon, KR;

Hyun-Jun Lee, Daejeon, KR;

In-Sik Shin, Gwangju, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 36/575 (2006.01); A61P 11/00 (2006.01); A61K 31/34 (2006.01); A61K 31/36 (2006.01); A61P 9/00 (2006.01); A61P 35/00 (2006.01); A61K 31/357 (2006.01); A61K 9/00 (2006.01); A61K 47/38 (2006.01);
U.S. Cl.
CPC ...
A61K 36/575 (2013.01); A61K 31/34 (2013.01); A61K 31/357 (2013.01); A61K 31/36 (2013.01); A61P 9/00 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); A61K 9/0019 (2013.01); A61K 9/0095 (2013.01); A61K 47/38 (2013.01);
Abstract

A pharmaceutical composition includes any of an extract of, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-α and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.


Find Patent Forward Citations

Loading…